Johnson & Johnson’s (J&J’s) proposed 340B rebate model, which has not received government approval, would give the drugmaker significantly more [...] …
Year: 2024
Missouri’s new law prohibiting drugmaker 340B contract pharmacy restrictions takes effect tomorrow, and the drug industry has responded with more [...] …
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...] …
If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that [...] …
SPONSORED CONTENT
Apexus remarked in October 2023, “It’s no longer a question of whether you’ll be audited; it’s a matter of when.” In the present 340B program climate, this assertion could apply to more than just HRSA audits.
…
The federal agency that oversees the 340B program did not approve drugmaker Johnson & Johnson’s (J&J’s) proposal to convert certain [...] …
In a move that would fundamentally alter the 340B program, pharmaceutical giant Johnson & Johnson (J&J) told hospitals this morning [...] …
A federal appeals court has dismissed AIDS Healthcare Foundation’s (AHF’s) lawsuit alleging Apexus, the 340B prime vendor, failed to negotiate [...] …
French drugmaker Sanofi has reportedly asked some hospitals for data relating to 340B purchases of a popular drug used to [...] …
SPONSORED CONTENT
Routine data analysis can be one of the most effective tools for navigating the complexities of the 340B landscape. Regular self-auditing can help ensure compliance, and even uncover new growth opportunities. This article explores how data analytics can transform
…